ALECENSA Drug Use Surveillance
Phase of Trial: Phase IV
Latest Information Update: 01 Apr 2019
Price : $35 *
At a glance
- Drugs Alectinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
- 01 Apr 2019 Safety results published in the Cancer Science.
- 06 Sep 2017 Status changed from active, no longer recruiting to completed.
- 01 Jul 2015 Status changed from recruiting to active, no longer recruiting as per University Hospital Medical Information Network - Japan.